ACLS three-lens brief
Evidence-based stock research on ACLS. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved +4.10% yesterday. · 50-day MA below 200-day MA (death-cross regime); price below both.
- Moved +4.10% yesterday.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 14.9pp over 30 days.
- Analyst mean target $132.00 — 19% above current (3 analysts).
- Reported earnings on 2026-11-05.
ACLS closed at $111.17 (+4.10%) as of 2026-11-12. Market cap: $3.43B. P/E (trailing) 33.1. Price is below the 50-day MA and below the 200-day MA. Positives: moved +4.10% yesterday.; analyst mean target $132.00 — 19% above current (3 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 14.9pp over 30 days.. Last quarter: Revenue $237.78M, net income $37.76M, free cash flow $40.50M.
Why three lenses on ACLS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACLS across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ACLS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACLS brief"></iframe>